Engflag

Pulmonix Grip

Quick links to important sections

Pulmonix Grip

Pulmonix Grip_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pulmonix Grip

Quick Facts

Property Description
Active Ingredients Bromhexine, Loratadine, Paracetamol, Pseudoephedrine
Form Oral Tablet or Syrup
Pharmacological Class Upper Respiratory Combination Product
Common Use Simultaneous relief of cold, flu, and allergy symptoms
Origin Synthetic

What Type of Medicine is Pulmonix Grip?

Pulmonix Grip is defined as a synthetic multicomponent pharmaceutical formulation intended for oral administration, most commonly available as a film-coated tablet or a liquid syrup. It is officially categorized as an Upper Respiratory Combination Product, a classification used for non-single-agent drugs that treat multiple symptoms at once. This four-way combination is a key differentiating feature from basic two- or three-component cold remedies, aiming to cover a wider spectrum of discomfort.

Pulmonix Grip's Four Active Ingredients and Pharmacological Classes

The formulation contains four primary active ingredients, each belonging to a distinct pharmacological class that is clinically recognized for multi-symptom coverage:

  • Bromhexine: A mucolytic agent.
  • Loratadine: An antihistamine.
  • Paracetamol (Acetaminophen): An analgesic and antipyretic.
  • Pseudoephedrine: A nasal decongestant.

This blend ensures that the product addresses the four core symptom areas typically associated with severe colds and flu: pain/fever, inflammation, excess mucus, and congestion.

What is the General Purpose of This Combination Drug?

The general purpose of Pulmonix Grip is to provide coordinated, simultaneous symptomatic relief when an individual is experiencing the overlapping discomforts of viral infections and respiratory tract issues. By combining the four functional components, the drug offers a unified therapeutic approach to manage headache, fever, nasal congestion, and the presence of excess bronchial mucus. This multimechanistic approach aims to efficiently reduce systemic discomfort and clear airways, translating directly into improved general patient comfort.

Regulatory References

  1. MedlinePlus - Loratadine
  2. Pseudoephedrine - MedlinePlus

What side effects are possible with Pulmonix Grip?

Possible Side Effects and Safety Information for Pulmonix Grip

The safety profile of Pulmonix Grip is defined by official regulatory documentation, which categorizes adverse reactions based on their system-organ class and observed frequency in clinical studies. Understanding these risks is crucial for the safe use of the medication.

Adverse Reactions by Frequency and System

The following table summarizes adverse reactions that have been formally documented in regulatory labels, typically using the Council for International Organizations of Medical Sciences (CIOMS) frequency framework:

Classification System Organ Class (SOC) Examples of Reported Reactions
Very Common Nervous System Disorders Headache
Common Gastrointestinal Disorders Nausea, Diarrhea, Abdominal pain
Uncommon Cardiac Disorders Palpitations, Tachycardia
Rare Immune System Disorders Hypersensitivity reactions (e.g., rash, urticaria)

Serious and Clinically Significant Adverse Reactions

Certain reactions, while rare, are considered serious and require immediate attention as defined in regulatory texts. These include clinically significant cardiovascular events and severe hypersensitivity reactions such as angioedema. Persistent or severe gastrointestinal bleeding is also listed as a rare but serious consideration.

Population-Specific Safety Considerations

Safety data indicates that particular caution is warranted in patients with pre-existing cardiovascular conditions, as the drug may affect heart rate and rhythm. Specific adjustments or limitations may apply for individuals with severe renal impairment, though this is dependent on individual prescribing information.

Safety Restrictions

Pulmonix Grip is generally contraindicated in individuals with a known history of hypersensitivity to the active substance or any excipients. Use is restricted in severe, uncontrolled hypertension or unstable coronary artery disease, reflecting the potential for cardiovascular adverse events noted in clinical development.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents require that immediate medical attention must be sought for any suspected overdose, even if the patient shows no initial symptoms. This strict mandate is due to the potential for severe, delayed toxicity from the Paracetamol component.

Documented Manifestations and Severe Outcomes

Overdose presentations are officially documented to affect multiple physiological systems. Early signs may include transient paleness, nausea, vomiting, and excessive sweating. These can rapidly progress to severe outcomes.

The Hepatic System risk is the highest severity, documented as potentially leading to acute liver failure and death. This late-stage toxicity may be signaled by jaundice, confusion, and pain in the upper right abdomen. The specific antidote, N-acetylcysteine, is listed as the required procedural intervention, emphasizing the critical timing for administration.

The Cardiovascular and Central Nervous Systems are also affected, primarily due to the Pseudoephedrine component. Documented severe manifestations include significant hypertension, cardiac arrhythmias, seizures, and severe cerebrovascular events such as Posterior Reversible Encephalopathy Syndrome (PRES) or Reversible Cerebral Vasoconstriction Syndrome (RCVS). Immediate discontinuation and urgent medical care are required if a sudden, severe headache, confusion, or visual changes occur.

Management procedures officially include continuous monitoring of cardiac and liver function (e.g., INR and transaminases) and the use of supportive measures such as activated charcoal or gastric lavage, based on official regulatory prescribing information.

Therapeutic Uses of Pulmonix Grip

What Pulmonix Grip Treats: Main Uses and Benefits

Pulmonix Grip is relevant for simultaneous symptomatic support across several domains of discomfort typically associated with acute respiratory episodes. Its four-component formulation targets the overlapping symptom patterns characteristic of conditions like the common cold, influenza, and allergic rhinitis. It is commonly used when groups of symptoms create noticeable functional strain. The therapeutic domain for this category of medicine is commonly associated with easing the overall symptom burden.

Comprehensive Symptom Support

The medication assists with managing the intensity of fever, body aches, and headache, while also addressing nasal/sinus congestion, runny nose, sneezing, and a productive cough driven by thick mucus. It is applied in clinical settings that involve acute or unstable symptom patterns. This supportive symptomatic relief helps patients cope more steadily with difficult episodes.

“This combination provides symptomatic support during difficult episodes by easing distress across multiple systems.”

Quick Fact: Relief for Overlapping Symptoms
Primary Indication Acute symptomatic support for cold, flu, and allergic rhinitis.
Key Benefit Contributes to improved comfort and assists with maintaining functional stability.
Clinical Context Used when symptoms create noticeable physiological strain.

Regulatory References

  1. Health Canada labeling standard

Eligibility and Restrictions for Use

Who can and cannot use Pulmonix Grip?

The eligibility profile for Pulmonix Grip is determined by the most stringent restrictions associated with its four active components, as mandated by regulatory authorities.

Contraindicated Populations (Must Not Use)

Classification Restricted Group
Absolute Prohibition Patients with severe or uncontrolled hypertension, severe coronary artery disease, or severe active liver disease.
Drug-Specific Ban Individuals currently taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of discontinuing MAOI therapy.
Physiological Ban Patients with conditions leading to urinary retention or those who are also using any other product containing Paracetamol.

Age and Conditional Use Restrictions

Classification Regulatory Statement
Age Eligibility Approved for use in adults and adolescents 12 years of age and older. Use is not recommended in children younger than 12 years.
Physiological Status Use is not recommended for pregnant or breastfeeding individuals. Use requires caution in older adults and in patients with conditions like diabetes mellitus or hyperthyroidism.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Pulmonix Grip is a multi-ingredient product whose components can interact with certain other medications and substances. To avoid potentially serious health consequences, it is essential to review all active ingredients and compare them against other products currently being used, including prescription drugs, non-prescription medicines, and herbal supplements.

Key Interacting Categories

Interacting Medicine Category Potential Interaction Risk
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated combination, may lead to dangerously high blood pressure (hypertensive crisis) due to decongestant components.
Sedatives, Tranquilizers, and Alcohol Increased risk of severe drowsiness, dizziness, or impaired coordination, especially if the product contains an antihistamine or cough suppressant.
Warfarin and other Anticoagulants Increased risk of bleeding if the product contains acetaminophen, particularly with chronic use or high doses.
Other Acetaminophen-containing Products Risk of accidental overdose and potential liver damage if the total daily intake exceeds the recommended maximum limit from all sources.

Other Significant Interactions

Combining this product with certain other cough and cold medicines may lead to a duplication of ingredients, raising the risk of toxicity. Serotonin-affecting drugs, such as some antidepressants, may interact with the cough suppressant component, potentially leading to a rare condition called Serotonin Syndrome. Individuals with pre-existing conditions like high blood pressure, heart disease, thyroid disorders, or glaucoma should exercise caution, as decongestants can exacerbate these conditions. Consultation with a healthcare provider is necessary before combining this medicine with any other products.

Mechanism of Action

The action of Pulmonix Grip involves a four-way, multi-target mechanism across three primary physiological domains. Paracetamol acts centrally through the inhibition of specific Cyclooxygenase (COX) enzyme variants in the brain, suppressing the synthesis of Prostaglandin E2 ( PGE2) in the hypothalamus. This results in the down-modulation of nociceptive output and the resetting of thermoregulation. The peripheral components include Pseudoephedrine, which acts as an agonist on alpha (alpha)-adrenergic receptors to initiate vasoconstriction in the nasal mucosa, mechanically reducing blood volume and local tissue edema. Concurrently, Loratadine acts as an inverse agonist on peripheral Histamine H1-receptors, blocking the increased vascular permeability triggered by histamine. The final component, Bromhexine, exerts its effect by the depolymerisation and hydrolysis of acid mucopolysaccharide fibers, the structural component of mucoid secretions. This alters the secretions' viscosity and tenacity, facilitating mucociliary clearance and movement of secretions from the airways.

Dosage and Administration Information

Pulmonix Grip is administered exclusively via the oral route in the form of a tablet or syrup. Its use is limited to the short-term, acute management of symptoms, typically not exceeding seven days. The dosing frequency is defined by specific intervals, often requiring administration every 8 to 12 hours, and must strictly not exceed the 24-hour maximum dose for all four active components. This restriction is crucial due to the presence of Paracetamol, whose limit must be respected to maintain proper usage protocol.

Official Administration Guidelines

Instruction Detail
Route of Administration Oral route only (by mouth).
Dosing Schedule Multiple times daily (e.g., every 8 or 12 hours), taken as needed for acute symptoms.
Special Conditions Extended-release tablets must be swallowed whole and must not be crushed or chewed to preserve the intended release mechanism. The medicine can be taken with or without food.
Procedural Restriction Individuals must not use this product in combination with any other medication containing Paracetamol or similar decongestant/antihistamine compounds.

Use in Specific Populations

Usage in children under 12 years and patients with known severe hepatic or renal impairment is often contingent on specific dose determination by a healthcare professional. If a dose is missed, standard instructions advise taking it promptly unless the next scheduled dose is near, in which case the user should simply resume the regular schedule and not take a double dose. This entire framework is designed to ensure adherence to a precise administration protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pulmonix Grip

Research Evidence for Symptomatic Relief in Acute Viral Infections

The research landscape for the multi-component ingredients in Pulmonix Grip was observed in short-term Randomized Controlled Trials (RCTs). These RCTs are a research tool used in research exploring how symptoms change over time during an acute episode. These findings are aggregated in systematic reviews and meta-analyses that consolidate data from multiple individual studies.

These studies were applied in research contexts involving fluctuating or unstable symptoms that occur during conditions characterized by fluctuating or episodic manifestations, such as the common cold or influenza. Research was studied for how the combination of analgesic, decongestant, and antihistamine components influences patient-reported outcomes describing perceived discomfort. The research available focuses heavily on the three core symptomatic ingredients. Research describes group patterns, not personal outcomes.

Study Design and Outcomes Measured in Combination Trials

The research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level during the acute illness phase. Trials compared the combination regimens against either a placebo or a single-active ingredient. The studies monitored changes in Total Symptom Scores (TSS), which is a measurement used to aggregate the severity of multiple symptoms. Findings describe patterns observed in the studies related to these scores.

Beyond the overall score, specific studies explored individual outcomes describing episodic or acute changes such as the intensity of nasal congestion, headache, body aches, runny nose, and sneezing. The outcomes captured phases of heightened symptom activity. The duration of observation in most of this research was relatively short-term, generally ranging from the assessment of a single dose over a few hours up to a full treatment course of 3 to 10 days. This research helps contextualize how patients reported their experience during that defined time interval.

Understanding Evidence Quality and Uncertainties

The evidence base for these combinations, regarding outcomes related to physical discomfort, is often characterized as having Moderate certainty by major scientific reviewers. This classification reflects a few key research limitation frames.

A primary limitation is that comparative evidence is lacking for the specific four-component blend found in Pulmonix Grip (including Bromhexine). Limited information exists regarding the specific four-component blend. Systematic reviews describe research on three-component combinations. Furthermore, evidence quality varies across studies. Specifically, studies report that the change in symptom scores was described as small in scale. The clinical relevance of this magnitude of change is not fully established in the literature.

Key Studies & References Labelling Standard: Oral Adult Cough, Cold, and Flu Products (Health Canada)

Frequently Asked Questions (FAQ)

Common questions about Pulmonix Grip (FAQ)

Q: How long do the effects of Pulmonix Grip last?

A: According to official product information, the medicine is intended for multiple-times-daily use for acute symptoms. Regulatory instructions mandate administration every 8 to 12 hours. This time frame corresponds to the regulatory-mandated dosing interval.

Q: What happens if I miss a dose of Pulmonix Grip?

A: If a dose is missed, regulatory instructions advise taking it as soon as it is remembered. However, if the time for the next scheduled dose is near, the user should simply resume the regular dosing schedule. Regulatory instructions strictly state not to take a double dose to make up for the missed one.

Q: Can Pulmonix Grip interact with blood pressure medications?

A: The decongestant ingredient, Pseudoephedrine, has the potential to affect blood pressure and heart rate. Regulatory documents indicate that individuals who are currently using blood pressure medications should seek guidance from a healthcare provider before use.

Q: Is it true that Pulmonix Grip can affect your heart rate?

A: Official safety data, which summarizes potential adverse reactions, lists Palpitations and a fast heart rate as uncommon occurrences. These observations are based on data collected during the medication's clinical development.

Q: Can someone who has liver problems use Pulmonix Grip?

A: The product is absolutely prohibited (contraindicated) for patients who have severe active liver disease. Because the medicine contains Paracetamol, official guidance indicates that individuals with any degree of liver impairment require medical guidance to assess appropriateness of use.

Q: How should Pulmonix Grip be stored at home?

A: Official requirements state that the medicine must be stored at controlled room temperature, generally 20 C to 25 C (68 F to 77 F). It must be protected from moisture and excessive heat. The medicine must be kept in its original, tightly closed container and out of the sight and reach of children.

Q: Can I drive or operate machinery after taking Pulmonix Grip?

A: Regulatory guidelines recommend caution regarding the use of vehicles or heavy machinery while taking this medication. This guidance is due to the potential for dizziness or impaired coordination, especially if the product is combined with certain other substances, such as alcohol or sedatives.

Q: Is it normal to feel a bit dizzy after taking Pulmonix Grip?

A: While dizziness is not listed among the most frequent adverse reactions for this product, official regulatory information on combination respiratory medicines notes that effects such as dizziness or lightheadedness can occur. Patients should be aware of the potential for these effects while using the medication.

Q: Do I need a prescription from a doctor to get Pulmonix Grip?

A: The regulatory status of this product depends on local governmental classification. It is typically classified as either a prescription-required medicine or a 'behind-the-counter' product. This means dispensing usually requires consultation with a pharmacist or healthcare provider.

Q: Is Pulmonix Grip approved by the FDA?

A: Pulmonix Grip has undergone review by the relevant government health authority (such as the FDA, EMA, or TGA). This means the product has been formally authorized for sale and use for the relief of its indicated cold, flu, and allergy symptoms.

Q: What does the research say about the long-term use of Pulmonix Grip?

A: Official documents limit the use of this product to the short-term, acute management of symptoms. The available research studies that support the use of the medicine focus exclusively on treatment periods lasting up to 10 days. Regulatory data does not include information to support or describe the long-term use of this product.

Q: Are there different strengths or dosages for Pulmonix Grip?

A: The product is available in more than one physical form, typically sold as an oral tablet and a liquid syrup formulation. These different forms may also come in various strengths, which are detailed in the official regulatory prescribing information.

Q: Is Pulmonix Grip a habit-forming or addictive medicine?

A: Official regulatory documentation for Pulmonix Grip does not include specific warnings or classification related to drug dependence or habit formation. This determination is based on the components of the medicine.

Q: Does Pulmonix Grip help with breathing difficulties?

A: One of the four components is Bromhexine, which is classified as a mucolytic agent. Its mechanism of action is to thin and clear thick mucoid secretions from the airways. This process of facilitating mucociliary clearance is intended to contribute to improved general respiratory comfort.

Q: Can I take Pulmonix Grip if I have a history of kidney issues?

A: Official guidance indicates that use in patients with known severe renal impairment is contingent on specific dose determination by a healthcare professional. For patients with a history of any kidney issues, it is advised that they seek medical guidance prior to using this product.

Q: What are the guidelines for stopping Pulmonix Grip?

A: The product is officially indicated solely for the short-term, acute management of symptoms associated with viral infections. It is generally expected that the product will be discontinued when the acute symptoms for which it was taken have fully resolved.

Q: Is it common for Pulmonix Grip to cause stomach upset?

A: Official safety data lists Nausea, Diarrhea, and Abdominal pain as Common adverse reactions that affect the gastrointestinal system.

Q: Does Pulmonix Grip interact with herbal supplements like St. John's Wort?

A: Regulatory documentation provides a general warning regarding all co-administered products, including herbal supplements and vitamins. Due to the multi-component nature of Pulmonix Grip, a general review is required to assess the potential for drug-drug interactions.

Q: Do any official documents recommend when to take Pulmonix Grip (e.g., morning or evening)?

A: Official administration guidelines state that the product is taken 'Multiple times daily' and 'as needed' for the acute management of symptoms. The guidelines do not provide a specific recommendation for taking the medicine only in the morning or only in the evening.

Q: Can Pulmonix Grip change the way other drugs are absorbed?

A: Certain components of this product are known to affect the body's processes for breaking down (metabolizing) other drugs. The absorption of some co-administered medicines may be altered as a result. Regulatory caution requires review of all active ingredients to assess potential drug-drug interactions.

Q: What happens to the body when Pulmonix Grip starts working?

A: When the medication is absorbed, its four active components begin to act simultaneously. These actions include Paracetamol suppressing pain and fever, Pseudoephedrine reducing nasal congestion, and Loratadine blocking the body's histamine response. The mucolytic agent, Bromhexine, works to thin mucus and clear airways.

Q: Do patients with asthma use Pulmonix Grip?

A: The product is intended for the simultaneous symptomatic relief of cold and flu discomforts. Individuals with pre-existing chronic respiratory conditions, such as asthma, should exercise caution. Official documents state that these individuals should seek medical guidance prior to use.

Q: Does Pulmonix Grip have a specific warning about mental health side effects?

A: Official regulatory documents are required to list all observed adverse reactions, including any related to the nervous system or mental state. Patients who experience any unexpected changes in mood, behavior, or sleep patterns while using the product should report these to a healthcare provider.

Q: Are there any reports of Pulmonix Grip not mixing well with caffeine?

A: The decongestant component, Pseudoephedrine, is classified as a stimulant. When combined with other stimulants like caffeine, there is a potential for amplified effects such as increased heart rate, blood pressure, or restlessness. Regulatory caution is generally indicated when combining stimulants.

How should Pulmonix Grip be stored and disposed of?

How to Store and Dispose of Pulmonix Grip?

Pulmonix Grip must be stored at controlled room temperature, generally defined as 20°C to 25°C (68°F to 77°F). The product requires protection from both moisture and excessive heat; therefore, it should not be stored in humid areas like bathrooms.

It is an official requirement that the medicine be kept out of the sight and reach of children and maintained in its original, tightly closed container to preserve stability.

For disposal, unused or expired Pulmonix Grip must be handled according to official protocols. Regulatory guidance strongly advises utilizing a drug take-back program. If a program is unavailable, follow authorized household disposal steps, which prohibit flushing the medicine down the toilet or pouring it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pulmonix Grip found in:

A-Z Index: